CEL-SCI Receives Government Grant to Develop CEL-1000 Against Herpes
VIENNA, Va., May 7 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) has been awarded a Phase I SBIR (Small Business Innovation
Research) grant from the National Institutes of Allergy and Infectious
Diseases (NIAID), National Institutes of Health (NIH), in the amount of
$162,000 for the further development of CEL-1000 against Herpes Simplex.
This work will be done in collaboration with the lab of Dr. Kenneth S.
Rosenthal of Northeastern Ohio Universities College of Medicine, Rootstown,
Ohio. Dr. Rosenthal is already working with the CEL-1000 peptide and recently
received a $1.1 million grant for collaborative studies with CEL-SCI for the
development of CEL-1000 as a possible treatment for viral encephalitis. Viral
encephalitis is a potentially lethal inflammation of the brain.
Last week, at the 16th International Conference on Antiviral Research,
CEL-SCI scientists and Dr. Kenneth S. Rosenthal presented animal protection
data against herpes simplex virus (HSV-1) infection. These tests utilized
CEL-SCI's CEL-1000 immune-modulating peptide. The new data shows evidence of
protection from disease symptoms and death after pre-treatment with CEL-1000
in a mouse skin herpes simplex virus infection model. This model closely
resembles the herpes simplex virus in humans as far as disease characteristics
and neuronal spread. An estimated 60 million Americans are infected with
Herpes Simplex and approximately 600,000 new cases occur every year.
The researchers reported that a single dose of CEL-1000, up to four weeks
prior to infection or up to three days after challenge, prevents or reduces
morbidity and mortality of HSV infections. In addition, CEL-1000 was also
shown to be effective without an adjuvant. Furthermore, in a separate animal
study using CEL-1000 as a melanoma vaccine, CEL-1000 acted as an adjuvant
itself. CEL-1000 was shown to also protect against malaria in animals in a
separate study conducted at the Naval Medical Research Center.
CEL-1000 is a modified version of a human immune-based protein known to
bind to both human and mouse immune cells and appears to act by enhancing the
host's immune protective immune response.
CEL-SCI Corporation is developing new immune system based treatments for
cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated"
and "expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which
could cause actual results to differ materially from those projected. Factors
that could cause or contribute to such differences include, an inability to
duplicate the clinical results demonstrated in clinical studies, timely
development of any potential products that can be shown to be safe and
effective, receiving necessary regulatory approvals, difficulties in
manufacturing any of the Company's potential products, inability to raise the
necessary capital and the risk factors set forth from time to time in CEL-SCI
Corporation's SEC filings, including but not limited to its report on Form 10-
K for the year ended September 30, 2002. The Company undertakes no obligation
to publicly release the result of any revision to these forward-looking
statements which may be made to reflect the events or circumstances after the
date hereof or to reflect the occurrence of unanticipated events.